Biotech and medical business blog

Visit BioHealth Investor

Genzyme & ISIS Amend Hereditary Cholesterol Pact (GENZ, ISIS)

Posted on June 24, 2008

Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) have finalized their license and collaboration agreement for mipomersen, a novel lipid-lowering drug discovered and developed by Isis that is in phase 3 clinical development. This is more of an amended terms to the deal rather than a new deal entirely.Genzyme will receive exclusive worldwide [...]...

Original article link


phase